Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients [clinicaltrials:NCT01374165]
Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients [clinicaltrials:NCT01374165]
Bio2RDF identifier
NCT01374165
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT01374165
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
biospec retention [clinicaltrials_vocabulary:biospec-retention]
Samples Without DNA
biospec_descr [clinicaltrials_vocabulary:biospec_descr]
Whole blood and urine
brief summary [clinicaltrials_vocabulary:brief-summary]
Prolong proposes to tes ...... 5 adult (>18 years) patients.
brief title [clinicaltrials_vocabulary:brief-title]
Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
This Phase I trial will ...... is no known risk for BSE/TSE.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2011-05-26T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2015-01-05T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT01374165
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
A Phase I Open Label, Unblinde ...... le Cell Disease (SCD) Patients
org study id [clinicaltrials_vocabulary:org-study-id]
SCIL-SANG-001
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
responsible party [clinicaltrials_vocabulary:responsible-party]
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2015-01-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
Study cancelled.
identifier
clinicaltrials:NCT01374165
title
Safety and Pharmacokinetics of SANGUINATE™ in Sickle Cell Disease (SCD) Patients
@en
type
label
Safety and Pharmacokinetics of ...... s [clinicaltrials:NCT01374165]
@en